During the 12th Five Year Plan period, Lianyungang Pharmaceutical Co., Ltd. continued to lead in new drug research and development

The reporter learned yesterday that during the "12th Five Year Plan" period, Lianyungang pharmaceutical enterprises applied for 552 new drugs and new products, 41 new drug certificates and 101 drug production approvals, ranking first in terms of quantity and quality in prefecture level cities across the country Lianyungang has well-known enterprises such as Hengrui pharmaceutical, Kangyuan pharmaceutical, Zhengda Tianqing, Haosen pharmaceutical, etc Among them, the annual R & D investment of Hengrui Pharmaceutical Co., Ltd., listed on the A-share market, accounts for more than 8% of the sales revenue It is the largest R & D and production base of anti-tumor drugs and surgical drugs in China At present, its market value is stable at about 100 billion yuan, ranking the forefront of listed enterprises in the national pharmaceutical industry Recently, Hengrui Pharmaceutical Co., Ltd will license new technologies for tumor immunotherapy with independent intellectual property rights to American enterprises for research and development This is the first time that Chinese pharmaceutical companies "export" biomedical technologies to the United States, and Hengrui Pharmaceutical Co., Ltd will gain hundreds of millions of dollars In addition, Lianyungang is also engaged in the modernization of traditional Chinese medicine Kangyuan Pharmaceutical Co., Ltd has been approved 46 new drugs, 50 varieties under research and 240 patents at home and abroad It is the enterprise with the largest number of invention patents in the Chinese medicine industry The pharmaceutical industry of Kangyuan is giving full play to its industrial advantages and is expanding the large-scale health field, including medical treatment, pension, physical examination, health management, etc Zhengda Tianqing Pharmaceutical Co., Ltd has outstanding strength in liver health drugs, and hausen Pharmaceutical Co., Ltd has a high market share in anti-tumor and psychiatric drugs.